Zomedica Corp stock (CA98959U1084): Record Q1 revenue lifts attention

Zomedica reported record first-quarter 2026 revenue of $8.8 million, up 35% year over year, ahead of a May 29 webinar on results and the companion-animal VetTech market.

Zomedica Corp reported record first-quarter 2026 revenue of $8.8 million, up 35% from a year earlier, and said it will discuss the results and the companion-animal VetTech market in a webinar on May 29, 2026. The company, which serves veterinarians with diagnostic and therapeutic products for companion animals, remains a small-cap name that can matter to U.S. investors watching animal health and specialty medtech trends.

As of: 19.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Zomedica Corp
• Sector/industry: Animal health, veterinary diagnostics and therapeutics
• Headquarters/country: Canada
• Core markets: Companion-animal veterinary clinics
• Key revenue drivers: Diagnostic instruments, consumables, and veterinary products
• Home exchange/listing venue: NYSE American (ZOM)
• Trading currency: USD

Zomedica Corp: core business model

Zomedica focuses on products for dogs, cats, and horses, with a business model centered on tools and therapies for clinical veterinarians. MarketBeat’s company profile describes Zomedica as a veterinary health company dedicated to improving the lives of companion animals through diagnostic and therapeutic solutions, while Robinhood lists a market capitalization near $105 million for the stock under ZOMDF and quotes the share price around $0.10 to $0.11 in late December 2025.

The latest business mix is important because the company’s revenue base is still relatively small, so quarterly changes can draw outsized attention. For U.S. investors, that makes Zomedica a niche animal-health play tied to clinic adoption rates, consumables usage, and product commercialization rather than a broad consumer brand story.

Main revenue and product drivers for Zomedica Corp

The most recent hard operating update in the available search results was the company’s first-quarter 2026 announcement, which said revenue reached a record $8.8 million, up 35% year over year. That update was highlighted in a May 15, 2026 news item and paired with a company webinar planned for May 29, 2026, giving investors a near-term catalyst to watch in addition to the reported growth trend.

Older third-party financial summaries also show the scale of the business: MarketBeat cited quarterly revenue of $7 million and EPS of negative $0.01 for a prior quarter, underscoring how volatile the earnings profile can be for a company at this stage. In practical terms, the market is likely to focus on whether revenue growth can keep expanding while operating losses narrow over time.

Zomedica’s positioning in companion-animal care may also matter beyond one quarter, because veterinary spending tends to be influenced by clinic economics, adoption of new diagnostics, and the broader willingness of pet owners to pay for treatment. For investors in the U.S. healthcare and medtech space, the company sits at the intersection of animal health, small-cap growth, and commercialization risk.

Conclusion

Zomedica’s latest revenue update gives the stock a clear near-term news trigger, especially for investors tracking small-cap animal health names. The company is still early in its commercialization path, so the balance between growth, margins, and recurring product demand remains central. With a webinar scheduled for May 29, 2026, the next company commentary could help clarify whether the first-quarter momentum is durable.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.